This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Tranzyme Pharma Announces Second Quarter 2012 Financial Results

Stocks in this article: TZYM

Financial Tables Follow

Tranzyme, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
(In thousands, except share and per share amounts)
         
  Three Months Ended Six Months Ended
  June 30, June 30,
  2012 2011 2012 2011
Licensing and royalty revenue  $ 1,340  $ 1,874  $ 2,783 $ 3,771
Research revenue 1,071 1,097 2,236 1,539
Total revenue 2,411 2,971 5,019 5,310
Operating expenses:        
Research and development 5,535 5,681 13,675 10,182
General and administrative 1,880 1,285 3,828 2,256
Total operating expenses 7,415 6,966 17,503 12,438
Operating loss  (5,004)  (3,995)  (12,484)  (7,128)
Interest expense, net  (624)  (399)  (1,056)  (819)
Other income (expense), net 19  (13)  (489)  175
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Net income (loss) per share— basic and diluted  $ (0.23)  $ (0.19)  $ (0.57)  $ (0.67)
Shares used to compute net loss per share— basic and diluted 24,607,888 23,217,146 24,604,595 11,610,927
         
Other comprehensive income (loss):        
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Foreign currency translation adjustment  (62)  (22)  (42)  13
Comprehensive income (loss)  $ (5,671)  $ (4,429)  $ (14,071)  $ (7,759)
 
 
Tranzyme, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
      
  June 30, December 31,
  2012 2011
Assets    
Current assets:    
Cash and cash equivalents  $ 36,387  $ 40,930
Accounts receivable, net 170 656
Investment tax credits receivable 456 838
Prepaid expenses and other assets 806 1,116
Total current assets 37,819 43,540
Investment tax credits receivable 189 --
Furniture, fixtures and equipment, net 1,069 1,171
Total assets  $ 39,077  $ 44,711
Liabilities and stockholders' deficit    
Current liabilities:    
Accounts payable  $ 2,670  $ 1,971
Accrued liabilities 2,070 1,549
Current portion of deferred revenue 2,930 5,574
Current portion of notes payable 2,169 238
Total current liabilities 9,839 9,332
Notes payable, less current portion 17,517 10,734
Other long-term liabilities 146 163
Total liabilities 27,502 20,229
Total stockholders' equity (deficit) 11,575 24,482
Total liabilities and stockholders' equity  $ 39,077  $ 44,711
CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
         
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com

3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs